| High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy A Bonjoch, P Echeverría, N Perez-Alvarez, J Puig, C Estany, B Clotet, ... Antiviral research 96 (1), 65-69, 2012 | 63 | 2012 |
| High prevalence of sarcopenia in HIV-infected individuals P Echeverría, A Bonjoch, J Puig, C Estany, A Ornelas, B Clotet, ... BioMed research international 2018, 2018 | 59 | 2018 |
| Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study … E Negredo, P Domingo, N Pérez-Álvarez, M Gutiérrez, G Mateo, J Puig, ... Journal of Antimicrobial Chemotherapy 69 (12), 3368-3371, 2014 | 58 | 2014 |
| Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa®), in antiretroviral-naïve patients: A 48 … P Echeverria, E Negredo, G Carosi, J Gálvez, JL Gómez, A Ocampo, ... Antiviral research 85 (2), 403-408, 2010 | 55 | 2010 |
| COVIDApp as an innovative strategy for the management and follow-up of COVID-19 cases in long-term care facilities in Catalonia: implementation study P Echeverría, MAM Bergas, J Puig, M Isnard, M Massot, C Vedia, R Peiró, ... JMIR public health and surveillance 6 (3), e21163, 2020 | 48 | 2020 |
| Peak bone mass in young HIV-infected patients compared with healthy controls E Negredo, P Domingo, E Ferrer, V Estrada, A Curran, A Navarro, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 65 (2), 207-212, 2014 | 42 | 2014 |
| Pulse wave velocity as index of arterial stiffness in HIV-infected patients compared with a healthy population P Echeverría, A Bonjoch, J Moltó, A Jou, J Puig, A Ornelas, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 65 (1), 50-56, 2014 | 39 | 2014 |
| Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels E Negredo, A Diez-Pérez, A Bonjoch, P Domingo, N Pérez-Álvarez, ... Journal of Antimicrobial Chemotherapy 70 (7), 2104-2107, 2015 | 32 | 2015 |
| Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV‐1‐infected subjects with dyslipidaemia P Echeverría, A Bonjoch, J Puig, A Ornella, B Clotet, E Negredo HIV medicine 18 (10), 782-786, 2017 | 31 | 2017 |
| A Specific Mobile Health Application for Older HIV-Infected Patients: Usability and Patient's Satisfaction J Puig, P Echeverría, T Lluch, J Herms, C Estany, A Bonjoch, A Ornelas, ... Telemedicine and e-Health 27 (4), 432-440, 2021 | 23 | 2021 |
| Nonnucleoside reverse-transcriptase inhibitor-vs ritonavir-boosted protease inhibitor–based regimens for initial treatment of HIV infection: a systematic review and … ÁH Borges, A Lundh, B Tendal, JA Bartlett, N Clumeck, D Costagliola, ... Clinical Infectious Diseases 63 (2), 268-280, 2016 | 22 | 2016 |
| High prevalence of signs of renal damage despite normal renal function in a cohort of HIV-infected patients: evaluation of associated factors A Bonjoch, J Juega, J Puig, N Pérez-Alvarez, A Aiestarán, P Echeverria, ... AIDS patient care and STDs 28 (10), 524-529, 2014 | 21 | 2014 |
| Comparison of two different strategies of treatment with zoledronate in HIV‐infected patients with low bone mineral density: single dose versus two doses in 2 years E Negredo, A Bonjoch, N Pérez‐Álvarez, A Ornelas, J Puig, C Herrero, ... HIV medicine 16 (7), 441-448, 2015 | 18 | 2015 |
| Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor … P Echeverría, A Bonjoch, J Puig, J Moltó, R Paredes, G Sirera, A Ornelas, ... PLoS One 9 (2), e84676, 2014 | 17 | 2014 |
| Potential prescribing issues among older HIV‐infected subjects in a Mediterranean cohort: Does the current prevalence give cause for concern? C Loste, J Moltó, N Pérez‐Álvarez, J Puig, P Echeverría, A Bonjoch, ... British Journal of Clinical Pharmacology 87 (3), 1310-1317, 2021 | 12 | 2021 |
| High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs E Negredo, K Langohr, A Bonjoch, N Pérez-Alvárez, C Estany, J Puig, ... Journal of Antimicrobial Chemotherapy 73 (9), 2452-2459, 2018 | 11 | 2018 |
| Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals E Negredo, V Estrada, P Domingo, MM Gutiérrez, GM Mateo, J Puig, ... Journal of Antimicrobial Chemotherapy 72 (3), 844-849, 2017 | 11 | 2017 |
| Ten-year safety with polyacrylamide gel used to correct facial lipoatrophy in HIV-infected patients E Negredo, J Puig, A Ornelas, P Echeverría, A Bonjoch, C Estany, ... AIDS Research and Human Retroviruses 31 (8), 817-821, 2015 | 11 | 2015 |
| Prospective study to assess progression of renal markers after interruption of tenofovir due to nephrotoxicity A Bonjoch, P Echeverría, N Perez-Alvarez, J Puig, C Estany, B Clotet, ... BioMed research international 2016, 2016 | 10 | 2016 |
| Evaluación y seguimiento de l a Estrategia Naos: conjunto mínimo de indicadores JM Ballesteros, N Pérez, J Quiles, P Echeverría, C Castelli, J Muñoz, ... Madrid: Ministerio de sanidad, política social e igualdad, 2011 | 9 | 2011 |
